ACS pharmacology & translational scienceOct 14, 2026

New RNA Treatments Targeting Inflammation in the Front Part of the Eye: How They Work and Their Medical Promise

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 15, 2026

Abstract

RNA-based therapeutics may offer targeted approaches for treating anterior segment ocular inflammatory disorders.

Conventional treatments for ocular inflammatory conditions primarily provide symptomatic relief and have limitations such as adverse effects and poor long-term efficacy.
RNA-based strategies include various forms like small interfering RNA, antisense oligonucleotides, and messenger RNA, which can regulate gene expression and inflammatory processes.
These therapies may enable precise modulation of key inflammatory mediators like cytokines and immune regulators involved in Th2-driven responses.
Recent advancements in nanotechnology have improved the stability and targeted delivery of RNA therapies to the ocular region.
Significant challenges remain, including ocular surface barriers and potential off-target effects, which need to be addressed for effective treatment.

Simplified

Anterior segment ocular inflammatory disorders, including conjunctivitis, keratitis, scleritis, dry eye disease, and anterior uveitis, represent a major cause of visual impairment worldwide. Conventional pharmacological therapies such as antihistamines, corticosteroids, and immunomodulators primarily provide symptomatic relief but are limited by their adverse effects, poor long-term efficacy, and lack of disease-modifying potential. In this review, RNA-based therapeutics are discussed in detail, emerging as promising and targeted approaches for modulating the molecular mechanisms underlying ocular anterior segment inflammatory conditions. These strategies include small interfering RNA (siRNA), short hairpin RNA (shRNA), antisense oligonucleotides (ASOs), messenger RNA (mRNA), microRNA (miRNA), and long noncoding RNA (lncRNA), each offering distinct mechanisms to regulate gene expression and inflammatory signaling pathways. RNA therapeutics enable precise silencing or modulation of key mediators such as cytokines, transcription factors, and immune regulators involved in Th2-driven and immune-mediated inflammatory responses. Recent advances in nanotechnology-based delivery systems, including lipid nanoparticles, polymeric carriers, and viral vectors, have significantly improved RNA stability, bioavailability, and targeted ocular delivery. Despite these advances, challenges such as ocular surface barriers, rapid tear clearance, enzymatic degradation, off-target effects, and potential immunogenicity remain significant hurdles. Overall, RNA-based therapies hold substantial potential as next-generation, disease-modifying treatments for anterior segment inflammatory disorders, including DED, warranting further translational and clinical investigation.

Full Text

Full text is available at the source.

View Full Text ↗

New RNA Treatments Targeting Inflammation in the Front Part of the Eye: How They Work and Their Medical Promise

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief